Databases Indications
Compound classes #trials/ # subjects RA Rheumatoid arthritis (RA) Psoriatic arthritis (PsA) or psoriasis (Ps) All biologics Newer synthetic DMARDS Older drugs as active control 94/ 38,460 Neuropathic Pain Diabetic neuropathy (DPN) Post herpetic neuralgia (PHN) Fibromyalgia All drugs approved or in development Older drugs as active control 57*/ 17,390* Osteoporosis Prevention and treatment of post menopausal osteoporosis Bisphosphonates, HRT, SERMs, calcitonin, PTH Newer therapies 78*/ 108,000* HCV Chronic HCV Long-acting pegylated interferons Newer small molecules Older drugs as active control 128/ 35,728 Depression Major depression All approved treatments All registration trials (minimize impact of publication bias) 75/17,667 Schizophrenia Schizophrenia monotherapy, and add-on therapy for refractory Schizophrenia Typical & atypical anti-psychotics Augmentation treatments 114/26203 Alzheimer's Alzheimer's Geriatric Cognitive Impairment NMDA Antagonists AChE Inhibitors Abeta Drugs & others in development 155/TBD Dyslipidemia Dyslipidemia, progression of atherosclerosis, prevention of CV events Statins, fibrates, cholesterol absorption inhibitors, Niacin Over 500/TBD Notice: The information contained in this electronic mail message is intended only for the use of the designated recipient. This message is privileged and confidential. and the property of GVK BIO or its affiliates and subsidiaries. If the reader of this message is not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this message in error and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone +91-40-66929999 and destroy any and all copies of this message in your possession (whether hard copies or electronically stored copies).
